Dicot Strenghten’s Team with new Supply Chain Director
Press release: Uppsala, October 4, 2019. Dicot AB (publ, developer of drugs targeting sexual dysfunction, today announced that the company has contracted Catarina Malmberg as its Supply Chain Director, effective of November 1, 2019. In this role Malmberg will be responsible for both supply of raw material and production through the entire supply chain.
“I am pleased to welcome Catarina to Dicot, whom will be a powerful resource for Dicot. She brings with her a very good track record from pharmaceutical production at Fresenius Kabi. Knowledge about handling of raw material from natural sources as well as collaboration with contractual manufacturers will fit extremely well with the need we have to secure volumes, quality and efficiency throughout the entire production chain," says Göran Beijer, CEO.
Catarina Malmberg brings over 20+ years of pharmaceutical experience including System projects (Manufacturing Execution Systems), Data integrity, Part 11 compliance, Business processes, Change management, Tech transfer, GxP, Design control, qualification and validation. She has worked with the entire chain in pharmaceutical manufacturing of terminally sterilized products for infusion, ranging from raw materials and API:s to finished products including packaging. Additionally, she has worked in QC Lab, QA-release, as a product specialist (mainly process/product chemistry and packaging chemistry) and project management.
She holds a Master's degree in Chemistry from Uppsala Univeristy.
For further information, please contact:
Julie Silber, CFO and Director of Investor Relations, Dicot / Gabriela Urquilla, Director of Communications & Vice President of Investor Relations
Tel: +46 (0)79 348 62 77 / +46 (0)72-396 72 19
E-mail: julie.silber@dicot.se / Gabriela.Urquilla@dicot.se
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.